Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

CABG still the ‘treatment of choice’ for patients with complex three-vessel CAD

The findings were presented at TCT 2021 and published in the New England Journal of Medicine.

TCT 2021 now offering free virtual attendance

The three-day event is sponsored by the Cardiovascular Research Foundation.

Confirmed: Watchman FLX LAAC device safe for nonvalvular AFib patients

New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.

Thumbnail

MitraClip an effective bridge strategy for advanced heart failure patients waiting for a heart transplant

The findings were presented Friday, Oct. 16, at TCT Connect 2020.

Thumbnail

Intravascular lithotripsy ‘safely and effectively’ facilitates stent delivery for CAD patients

The findings were presented Thursday, Oct. 15, at TCT Connect 2020.

Thumbnail

Bivalirudin bests heparin for treating heart attack patients undergoing PCI

The findings were presented Wednesday, Oct. 14, during TCT Connect 2020. 

Thumbnail

TCT 2020 to be held virtually due to COVID-19 concerns

TCT 2020, now known as TCT Connect, is scheduled to broadcast Oct. 14-18, 2020.

Thumbnail

Orsiro stent continues to outperform Xience at 3 years

Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.